An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis

by Marion Zillhardt, James G. Christensen, Ernst Lengyel
Published 2010-01-01

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance.

by Melissa Dolan, Michalis Mastri, Amanda Tracz, James G Christensen, Gurkamal Chatta, John M L Ebos
Published 2019-01-01

A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal

by Michalis Mastri, Amanda Tracz, Christina R. Lee, Melissa Dolan, Kristopher Attwood, James G. Christensen, Song Liu, John M.L. Ebos
Published 2018-12-01

Inhibition of c-Met as a Therapeutic Strategy for Esophageal Adenocarcinoma

by Gregory A. Watson, Xinglu Zhang, Michael T. Stang, Ryan M. Levy, Pierre E. Queiroz de Oliveira, William E. Gooding, James G. Christensen, Steven J. Hughes
Published 2006-11-01

Correction: A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation

by Nathan V. Lee, Maruja E. Lira, Adam Pavlicek, Jingjing Ye, Dana Buckman, Shubha Bagrodia, Sreesha P. Srinivasa, Yongjun Zhao, Samuel Aparicio, Paul A. Rejto, James G. Christensen, Keith A. Ching
Published 2012-01-01

Correction: A Novel SND1-BRAF Fusion Confers Resistance to c-Met Inhibitor PF-04217903 in GTL16 Cells though MAPK Activation.

by Nathan V. Lee, Maruja E. Lira, Adam Pavlicek, Jingjing Ye, Dana Buckman, Shubha Bagrodia, Sreesha P. Srinivasa, Yongjun Zhao, Samuel Aparicio, Paul A. Rejto, James G. Christensen, Keith A. Ching
Published 2012-01-01

A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.

by Nathan V Lee, Maruja E Lira, Adam Pavlicek, Jingjing Ye, Dana Buckman, Shubha Bagrodia, Sreesha P Srinivasa, Yongjun Zhao, Samuel Aparicio, Paul A Rejto, James G Christensen, Keith A Ching
Published 2012-01-01